Quanzhou, China, Oct. 30, 2025 (GLOBE NEWSWIRE) -- INLIF LIMITED (Nasdaq: INLF) (the “Company” or “INLIF”), a company engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms, today announced that on October 27, 2025, it received a deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”). The Notice informed the Company that, based upon the closing bid price of the ...

Shelton, CT, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Hubbell Incorporated (NYSE: HUBB) (“Hubbell” or the “Company”) today announced that it has successfully priced an offering of $400 million aggregate principal amount of 4.80% senior notes maturing in 2035. The offering is expected to close on November 14, 2025, subject to customary closing conditions. Net proceeds from the offering, together with cash on hand, are expected to be used to redeem in full all of the Company’s outstanding 3.350% Senior Notes due 20 ...

ISELIN, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Provident Financial Services, Inc. (NYSE:PFS), please note that in the first paragraph, the payable date for the quarterly cash dividend should be November 28, not November 18 as previously stated. The corrected release follows: Provident Financial Services, Inc. (NYSE:PFS) (the “Company”) Board of Directors declared a quarterly cash dividend of $0.24 per common share payable on November 28, 2025 to ...

New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on transformational business developm ...

STAMFORD, Conn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Patriot Bank, N.A. (“Patriot Bank”) and its holding company Patriot National Bancorp, Inc. (NASDAQ: PNBK) are pleased to announce Thedora Nickel as the new Chair of the Patriot Bank Board of Directors and President and Chief Executive Officer Steven Sugarman as Chair of the Patriot National Bancorp Inc. Board of Directors. Thedora Nickel has served on the Board of Patriot Bank since May 19, 2025, and has over 30 years of bank experience, with deep expertise ...

Core Viewpoint - Arhaus, Inc. is set to release its third quarter 2025 financial results on November 6, 2025, before the market opens, followed by a conference call to discuss the results [1]. Company Overview - Arhaus, founded in 1986, is a growing lifestyle brand and omnichannel retailer specializing in premium artisan-crafted home furnishings [3]. - The company employs a proprietary model that involves direct design and sourcing from leading manufacturers and artisans globally, offering exclusive heirloom quality products that are sustainably sourced and built to last [3]. - Arhaus operates over 100 showroom and design studio locations across the United States and provides complimentary in-home design services through a team of interior designers [3]. - The company is recognized for its innovative design, responsible sourcing, and client-first service [3].

Core Insights - Celldex announced positive data from the Phase 1 study of CDX-622, a bispecific antibody targeting inflammation and fibrosis pathways [1][2] - The study demonstrated good tolerability, a favorable pharmacokinetic profile, and significant reductions in serum tryptase levels, indicating effective mast cell inhibition [1][6] - The company plans to advance the study to the next phase, testing multiple ascending doses and initiating a Phase 1b study in asthma patients [2][4] Study Design and Results - The Phase 1 trial is a randomized, double-blind, placebo-controlled, dose escalation study assessing safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CDX-622 [4][7] - Part 1 enrolled 32 participants across 4 cohorts, receiving single ascending intravenous doses of CDX-622 (0.3, 1.0, 3.0, and 9.0 mg/kg) over a 12-week observation period [4][6] - Data from Part 1 were presented, and enrollment for Part 2 is ongoing, with results from Parts 2 and 3 expected in Q3 2026 [4][6] Mechanism and Therapeutic Potential - CDX-622 targets two validated pathways: neutralizing TSLP and depleting mast cells via SCF starvation, potentially offering enhanced therapeutic benefits for inflammatory and fibrotic disorders [5][6] - The antibody showed a serum half-life of approximately 18 days at 9 mg/kg, with no evidence of immunogenicity or dose-limiting toxicities observed [6][2] - A single dose led to a rapid and sustained decrease of about 50% in circulating tryptase, consistent with systemic mast cell inhibition [6]

Core Insights - MPS reported record quarterly revenue of $737.2 million for Q3 2025, reflecting a 10.9% increase from Q2 2025 and an 18.9% increase year-over-year from Q3 2024 [3][8][13] - The company's diversified market strategy contributed to revenue growth across all end markets, showcasing resilience in its product portfolio and customer focus [8][12] Financial Performance - Revenue for Q3 2025 was $737,176,000, with a gross margin of 55.1%, flat compared to Q2 2025 [3][20] - Operating expenses increased to $211,045,000, up 4.9% quarter-over-quarter and 17.6% year-over-year [3][23] - Net income for Q3 2025 was $178,274,000, representing a 33.3% increase from Q2 2025 and a 23.4% increase year-over-year [3][25] Non-GAAP Metrics - Non-GAAP net income for Q3 2025 was $227,114,000, with a diluted EPS of $4.73, up 12.4% from Q2 2025 [5][25] - Non-GAAP gross margin was reported at 55.5%, consistent with Q2 2025 [22][36] Revenue by End Market - Enterprise Data revenue reached $191.5 million, up 33% from Q2 2025, driven by sales of power management solutions for AI applications [14] - Automotive revenue was $151.5 million, a 4.4% increase from Q2 2025, with a year-over-year growth of 36.1% [18] - Storage and Computing revenue decreased by 4.5% from Q2 2025 to $186.6 million, but showed a year-over-year increase of 29.6% [19] Cash Flow and Balance Sheet - Cash, cash equivalents, and short-term investments totaled $1,269.5 million at the end of Q3 2025, up from $1,146.1 million in Q2 2025 [27][31] - Operating cash flow for Q3 2025 was $239.3 million, slightly higher than $237.6 million in Q2 2025 [27][31] Business Outlook - For Q4 2025, MPS forecasts revenue in the range of $730 million to $750 million, with a GAAP gross margin between 54.9% and 55.5% [33][48]

Core Insights - Alignment Healthcare, Inc. reported strong financial results for Q3 2025, surpassing guidance across all key metrics for the third consecutive quarter [2][6][7] - The company achieved a revenue of $993.7 million, representing a 43.5% increase year-over-year, and maintained 100% of its members in plans rated 4 stars or higher for the second consecutive year [6][7] Financial Highlights - Health plan membership reached approximately 229,600, up 25.9% year-over-year [7] - Adjusted gross profit for Q3 2025 was $127.5 million, with an income from operations of $7.7 million [7] - Adjusted EBITDA was reported at $32.4 million, with a net income of $3.7 million [7][8] Outlook - For Q4 and the full fiscal year 2025, the company projects health plan membership between 232,500 and 234,500, revenue between $995 million and $1,010 million, and adjusted EBITDA ranging from $(9) million to $(1) million [4] - The full-year revenue outlook is expected to be between $3.931 billion and $3.946 billion [4] Operational Metrics - The medical benefits ratio based on adjusted gross profit was 87.2% [7] - The company reported total medical expenses of $868.0 million for Q3 2025, compared to $613.4 million in Q3 2024 [17] Cash Flow and Balance Sheet - Cash and cash equivalents at the end of Q3 2025 were $618.1 million, up from $432.9 million at the end of 2024 [14][20] - Total assets increased to $1.102 billion from $782.1 million at the end of 2024 [14]

Core Insights - Prime Medicine, Inc. is set to host a virtual event on November 12, 2025, to discuss its liver disease franchise, particularly focusing on Wilson's Disease [1][2] - The company plans to file an investigational new drug (IND) and/or clinical trial application (CTA) for PM577, targeting H1069Q-driven Wilson's Disease, in the first half of 2026, with initial clinical data expected in 2027 [1][9] Company Overview - Prime Medicine is a biotechnology company focused on developing one-time curative genetic therapies using its proprietary Prime Editing platform, which allows precise and efficient gene editing [4][5] - The company aims to address a range of genetic mutations across various tissues and diseases, potentially unlocking thousands of indications [4][5] Strategic Focus - Prime Medicine is concentrating on high-value programs in liver, lung, and immunology and oncology, with a clear clinical development path for each [5] - The company intends to leverage the modularity of its Prime Editing platform to accelerate the development of therapies for Wilson's Disease and other genetic conditions [8][9] Market Opportunity - There is currently no curative therapy for Wilson's Disease, and existing treatments face challenges related to compliance, cost, and tolerability [8] - Prime Editing has the potential to provide a durable cure for Wilson's Disease by precisely addressing its genetic causes [8][9]